Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1-Year Open-Label Safety Extension Study of Pregabalin in Anxiety Disorders
2004-000954-22Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pregabalin in generalized anxiety disorder (GAD), Social Anxiety Disorder (SAD) and panic disorder, sponsored by Pfizer. Primary endpoint: Clinical Global Impression of Severity score. Started Sep 2004; status: completed.
02
Drugs
pregabalin
03
Conditions
generalized anxiety disorder (GAD)Social Anxiety Disorder (SAD)panic disorder
Beyond the preview
Go deeper on 2004-000954-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000954-22.